Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675, 206), a fully human monoclonal antibody

Expert Opinion on Investigational Drugs

Volumn 17, Issue 3, 2008, Pages 371-385

  Camacho, Luis H ^a  

^a Oncology Consultants PA ^*  (United States)

Author keywords

Cancer; CLTA 4; CP 675,206; CTLA4; Cytotoxic T lymphocyte associated antigen; Immunotherapy; Melanoma; Ticilimumab; Tremelimumab

Indexed keywords

ANTIHISTAMINIC AGENT; ATROPINE; CORTICOSTEROID; CPG 7909; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DIPHENOXYLATE; DOCETAXEL; EXEMESTANE; GEMCITABINE; IMMUNOGLOBULIN G; IPILIMUMAB; LOPERAMIDE; STEROID; SUNITINIB; TEMOZOLOMIDE; TICILIMUMAB; ANTINEOPLASTIC AGENT; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ASTHMA; AUTOIMMUNITY; BLOOD TOXICITY; BLOOD TRANSFUSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLITIS; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYTOKINE RELEASE; DERMATITIS; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EYE TOXICITY; FATIGUE; FLU LIKE SYNDROME; GASTRITIS; GASTROINTESTINAL TOXICITY; HUMAN; HUMIDIFIER; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOPITUITARISM; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; KIDNEY CANCER; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALAISE; MELANOMA; MORNING STIFFNESS; MULTIPLE DRUG DOSE; MYALGIA; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULAR PRURITUS; OVERALL SURVIVAL; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REVIEW; SARCOIDOSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; SURVIVAL TIME; T LYMPHOCYTE; THYROID DISEASE; UVEITIS; VITILIGO; ANIMAL; IMMUNOLOGY; NEOPLASM; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 40949116644     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.3.371     Document Type: Review

References (70)

1. Camacho LH, Bacik J, Cheung A, Spriggs DR. Presentation and subsequent publication rates of phase I oncology clinical trials. Cancer 2005;104:1497-504
2. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
4. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15
6. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change? Cancer 2007;109:455-64
7. Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol 1997;24:S39-43
8. Sasse AD, Sasse EC, Clark LG, et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007;CD005413
9. Moschos S, Varanasi S, Kirkwood JM. Interferons in the treatment of solid tumors. Cancer Treat Res 2005;126:207-41
10. Xue SA, Stauss HJ. Enhancing immune responses for cancer therapy. Cell Mol Immunol 2007;4:173-84
11. Billingham RE, Brent L, Medawar PR. Actively acquired tolerance of foreign cells. Nature 1953;172:603-6
12. Medawar PB. Immunological tolerance. Science 1961;133:303-6
13. Taams LS, Palmer DB, Akbar AN, et al. Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology 2006;118:1-9
14. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-77
15. Alegre ML, Noel PJ, Eisfelder BJ, et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol 1996;157:4762-70
16. Alegre ML, Shiels H, Thompson CB, Gajewski TF. Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol 1998;161:3347-56
17. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002;16:23-35
18. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-8
19. McCoy KD, Hermans IF, Fraser JH, et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-incluced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help. J Exp Med 1999;189:1157-62
20. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol 1997;9:396-404
21. Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily - CTLA-4 Nature 1987;328:267-70
22. Dariavach P, Mattei MG, Golstein P, Lefranc MP. Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. Eur J Immunol 1988;18:1901-5
23. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-65
24. Bashyam, H. CTLA-4: from conflict to clinic. J Exp Med 2007;204:1243
25. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7
26. Khattri R, Auger JA, Griffin MD, et al. Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses. J Immunol 1999;162:5784-91
27. Chistiakov DA, Turakulov RI. CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol 2003;31:21-36
28. Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes Immun 2000;1:170-84
29. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100:8372-7
30. Gomez-Navarro J, Antoina S, Sosman J, et al. Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study. Poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5 2007, Chicago, IL, USA. Abstract 8524
31. Ribas A, Antonia S, Sosman J, et al. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an and-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma [oral]. Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5 2007, Chicago, IL, USA. Abstract 3000
32. Hersh EM, Weber J, Powderly J, et al. A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma. J Clin Oncol 2004;23(Suppl):709. Abstract 7511
33. Ribas A, Hanson D, Noe D, et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 2007;12:873-83
34. Canniff PC, Donovan CB, Burkwit JJ, et al. CP-675,205 anti-CTLA4 antibody clinical candidate enhances IL-2 production in cancer patient T cells in vitro regardless of tumor type or stage of disease. Proc Am Assoc Cancer Res 2004;45 Abstract 709
35. Hanson DC, Canniff PC, Primiano MJ, et al. Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. Proc Am Assoc Cancer Res 2004;45:Abstract 3802
36. Jakobovits A, Amado RG, Yang X, et al. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007;25:1134-43
37. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6
38. Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2006;60:2444-8
39. Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 1999;96:15074-9
40. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by auroimmune depigmentation. J Exp Med 1999;190:355-66
41. Sabel MS, Hess SD, Egilmez NK, et al. CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice. Cancer Immunol Immunother 2005;54:944-52
42. Reuben JM, Lee BN, Li C, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 2006;106:2437-44
43. Pavlov D, Bulanhagui C, Wallis N, Gomez-Navarro J. Immune-related adverse events in patients with melanoma treated with tremelimumab (CP-675,206) [oral presentation]. Presented at the International Society for Biological Therapy of Cancer 22nd Annual Meeting; November 2-4 2007
44. Antonia S, Sosman J, Kirkwood JM, et al. Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206. Poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology. June 1-5 2007, Chicago, IL, USA. Abstract 3038
45. Olesen M, Eriksson S, Bohr J, et al. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut 2004;53:536-41
46. Davis TA, Tchekmedyian S, Korman A, et al. MDX-010 (human anti-CTLA4): a phase 1 trial in hormone refractory prostate carcinoma (HRPC). Proc Am Soc Clin Oncol 2002;21:19a Abstract74
47. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005;28:593-8
48. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-9
49. Shaw SA, Camacho LH, McCutcheon IE, Waguespack SG. Image in endocrinology: transient hypophysitis after cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade. J Clin Endocrinol Metab 2007;92:1201-2
50. Straatsma BR, Nusinowitz S, Young TA, et al. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol 2007;143:958-69
51. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T-lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005;12:1005-16
52. Robinson MR, Chan CC, Yang JC, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 2004;27:478-9
53. Islam SM, El-Sheikh HF, Tabbara KF. Anterior uveitis following combined vaccination for measles, mumps and rubella (MMR): a report of two cases. Acta Ophthalmol Scand 2000;78:590-2
54. Wertheim M, Astbury N. Bilateral uveitis after intravesical BCG immunotherapy for bladder carcinoma. Br J Ophthalmol 2002;86:706
55. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53
56. Doyle MK, Berggren R, Magnus JH. Interferon-induced sarcoidosis. J Clin Rheumatol 2006;12:241-8
57. Hendrickx BW, van Herpen CM, Bonenkamp JJ, et al. Positive positron emission tomography scan in sarcoidosis and two challenging cases of metastatic cancer. CASE 1. Mediastinal sarcoidosis in a melanoma patient treated with interferon. J Clin Oncol 2005;23:8906-7
58. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14
59. Hamid O, Urba WJ, Yellin M, et al. Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. Poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5 2007, Chicago, IL, USA. Abstract 8525
60. Weber JS, Hersh EM, Yellin M, et al. The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma. Poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5 2007, Chicago, IL, USA. Abstract 8523
61. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15
62. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92
63. Comin-Anduix B, Lee Y, Jalil J, et al. Immunological assays to differentiate responders from nonresponders after CTLA blockade with CP-675,206 [abstract]. Poster presented at the International Society for Biological Therapy of Cancer 21st Annual Meeting, October 6-9 2006, Los Angeles, CA, USA. Abstract 17
64. Maker AV, Atria P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005;175:7746-54
65. Weber J, Targan S, Scotland R, et al. Phase Il trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide, vaccine for resected stages IIIC and IV melanoma. J Clin Oncol 2006;24(,Suppl);102s. Abstract 2510
66. O'Mahony D, Morris JC, Quinn C, et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 2007;13:958-64
67. Small EJ, Higano C, Tchekmedyian NS, et al. Randomized phase II study comparing 4 monthly doses of ipilimumab (MDk-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. J Clin Oncol 2006;24(Suppl): 18S. Abstract 4609
68. Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 2007;12:1084-95
69. Kaufmann DE, Kavanagh DG, Pereyra F, et al. Upregulation of CTLA-4 by HIV-specific CD4(+) T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007;8:1246-54
70. Camacho LH, Ribas A, Glaspy JA, et al. Phase I clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients with advanced solid malignancies [oral presentation]. Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA, USA. Abstract 2505